Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Risheng Que

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3242-5639; OpenAlex author ID A5085378930. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 16

  1. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Co-author DOI 10.1200/jco-26-01393↗
  2. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Co-author DOI 10.1016/j.canlet.2025.217658↗
  3. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Co-author DOI 10.1016/j.ccell.2025.09.009↗
  4. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone… Co-author DOI 10.1186/s12885-023-10529-7↗
  5. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Co-author DOI 10.1245/s10434-023-13383-w↗
  6. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Co-author DOI 10.1186/s12885-022-09974-7↗
  7. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  8. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. Co-author DOI 10.1002/jmri.27024↗
  9. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  10. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.009↗
  11. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
  12. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Co-author DOI 10.1634/theoncologist.2018-0696↗
  13. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Co-author DOI 10.1016/j.canlet.2017.07.012↗
  14. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pa… Co-author DOI 10.1631/jzus.b1500305↗
  15. [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
  16. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/1477-7819-11-219↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 10 shared papers, 2016–2023 · strength 1.00
  2. Xueli Bai · 8 shared papers, 2019–2026 · strength 0.94
  3. Tingbo Liang · 4 shared papers, 2023–2026 · strength 0.76
  4. Xiang Li Ma · 4 shared papers, 2023–2025 · strength 0.69
  5. Guoliang Qiao · 3 shared papers, 2025–2026 · strength 0.61
  6. Tianan Jiang · 3 shared papers, 2025–2026 · strength 0.61
  7. Xiang Li · 7 shared papers, 2017–2020 · strength 0.57
  8. Xueli Bai · 4 shared papers, 2016–2025 · strength 0.52
  9. Qi Zhang · 5 shared papers, 2019–2023 · strength 0.50
  10. Qi Zhang · 3 shared papers, 2017–2025 · strength 0.45
  11. Tao Ma · 5 shared papers, 2017–2020 · strength 0.40
  12. Wei Chen · 3 shared papers, 2020–2022 · strength 0.32
  13. Xiaozhen Zhang · 2 shared papers, 2020–2026 · strength 0.31
  14. Min Zhang · 2 shared papers, 2023 · strength 0.29
  15. Jianying Lou · 4 shared papers, 2016–2019 · strength 0.29
  16. Qichun Wei · 3 shared papers, 2016–2022 · strength 0.27
  17. Qihan Fu · 2 shared papers, 2020–2023 · strength 0.24
  18. Mengyi Lao · 2 shared papers, 2020–2022 · strength 0.23
  19. Ri‐Sheng Yu · 3 shared papers, 2016–2020 · strength 0.22
  20. Lei Zheng · 3 shared papers, 2017–2019 · strength 0.22
  21. Tianyu Tang · 2 shared papers, 2020 · strength 0.18
  22. Tao Wei · 2 shared papers, 2019–2020 · strength 0.18
  23. Jiaqi Yang · 2 shared papers, 2019–2020 · strength 0.17
  24. Yinan Shen · 2 shared papers, 2019–2020 · strength 0.16
  25. Meng Wang · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.